

INTREXON CORP  
Form 8-K/A  
October 30, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K/A**  
**AMENDMENT NO. 1**  
**TO CURRENT REPORT**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 30, 2013 (September 30, 2013)**

**INTREXON CORPORATION**  
**(Exact Name of Registrant as Specified in Charter)**

**Virginia**  
**(State or Other Jurisdiction)**

**001-36042**  
**(Commission)**

**26-0084895**  
**(IRS Employer)**

**of Incorporation)** **File Number)** **Identification No.)**  
**20374 Seneca Meadows Parkway, Germantown, Maryland 20876**

**(Address of Principal Executive Offices) (Zip Code)**

**(301) 556-9900**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Explanatory Note**

On October 4, 2013, Intrexon Corporation ( Intrexon ) filed a Current Report on Form 8-K to disclose Intrexon's entry into a worldwide Exclusive Channel Collaboration Agreement (the ECC ) with S & I Ophthalmic, LLC ( JV ), a joint venture between Intrexon and an indirect subsidiary ( Sun Pharmaceutical Subsidiary ) of Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases.

Intrexon is filing this Current Report on 8-K/A to file under Item 9.01 the ECC and the Limited Liability Agreement of JV. Except for the filing of the exhibits under Item 9.01, the Current Report on Form 8-K filed on October 4, 2013 is not being amended or updated in any manner.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
10.1*	Exclusive Channel Collaboration Agreement, dated as of September 30, 2013, between Intrexon and S & I Ophthalmic, LLC.
10.2*	Limited Liability Company Agreement of S & I Ophthalmic, LLC, dated September 30, 2013, between Intrexon and Caraco Pharmaceutical Laboratories Ltd.
99.1**	Press release of Intrexon Corporation and Sun Pharmaceutical Industries Ltd. dated October 1, 2013.

\* Portions of this exhibit have been omitted pursuant to a request for confidential treatment and this exhibit has been submitted separately to the Securities and Exchange Commission.

\*\* Previously filed.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 30, 2013

**INTREXON CORPORATION**

By: /s/ Donald P. Lehr  
Donald P. Lehr  
Chief Legal Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
10.1*	Exclusive Channel Collaboration Agreement, dated as of September 30, 2013, between Intrexon and S & I Ophthalmic, LLC.
10.2*	Limited Liability Company Agreement of S & I Ophthalmic, LLC, dated September 30, 2013, between Intrexon and Caraco Pharmaceutical Laboratories Ltd.
99.1**	Press release of Intrexon Corporation and Sun Pharmaceutical Industries Ltd. dated October 1, 2013.

\* Portions of this exhibit have been omitted pursuant to a request for confidential treatment and this exhibit has been submitted separately to the Securities and Exchange Commission.

\*\* Previously filed.